Social media

At ICON, we believe that the most valuable learning comes from shared experience. Our teams recently came together for a Clinical Research Associate Masterclass led by Hristina Gogova and Loreta Ivanova. The session off...

Many therapeutic areas lack complete head to head data. Our whitepaper outlines how network meta analysis constructs a connected evidence base by integrating direct and indirect comparisons, provided studies share a su...

Many therapeutic areas lack complete head to head data. Our whitepaper outlines how network meta analysis constructs a connected evidence base by integrating direct and indirect comparisons, provided studies share a su...

Join ICON at World Vaccine Congress 2026 as we share our latest insights in HIV vaccine and therapeutic development. With 30+ HIV studies, 13,800+ participants, and 20+ years of operational experience across 27 African a...

Latest issue out now. Do you struggle to keep on top of regulatory changes affecting the world of medicine and medical device clinical trials? Join thousands of subscribers who have discovered the convenience of our fr...

Latest issue out now. Do you struggle to keep on top of regulatory changes affecting the world of medicine and medical device clinical trials? Join thousands of subscribers who have discovered the convenience of our ...

China’s biotech sector continues its strong growth trajectory, creating new opportunities for global innovation. In this latest BioXconomy analysis, Yao Zhong, Vice President and General Manager for ICON China Mainland a...

China’s biotech sector continues its strong growth trajectory, creating new opportunities for global innovation. In this latest BioXconomy analysis, Yao Zhong, Vice President and General Manager for ICON China Mainland a...

Bioanalytical strategy is central to successful biosimilar development. Our latest spotlight explores how scientific advancements are helping teams strengthen comparability, improve accuracy and accelerate development ti...

Advances in biosimilar development demand bioanalytical strategies that are robust, adaptive and scientifically rigorous. Discover 6 elements of a successful strategy to support biosimilar development and how innovators ...

As ADCs expand into new indications—including rare cancers and potential autoimmune applications—regulatory pathways continue to adapt. ICON’s regulatory expert, Eilidh Mayer, examines how accelerated approvals, orphan ...

With increasing approvals across Asia and beyond, ADCs remain one of the most dynamic areas in oncology innovation. ICON’s new publication highlights the critical elements of regulatory engagement, dose optimisation and ...